Signal mechanisms in inflammatory processes - 18/05/2021

Newly discovered substances activate the inflammasome in macrophages

Low-grade chronic inflammation caused by components of the innate immune system may increase the risk of developing a variety of diseases in the long term. In their search for the signalling mechanisms underlying these inflammatory processes, Prof. Dr. Olaf Groß' research group at the Freiburg University Medical Centre discovered new active substances with immunostimulatory properties that may open up additional possibilities in cancer…

The working group around Dr. Philipp Rathert at the Institute for Biochemistry and Technical Biochemistry investigates the regulation of epigenetic networks of certain cancers and ways of treating them. The working group published its new findings in April.

The amount of plastic waste increases every year. Some of this waste is due to plastic packaging used to protect food. As part of the “BioActiveMaterials” project, researchers at the Fraunhofer-Gesellschaft have developed an eco-friendly coating for paper packaging. With this, not only is plastic saved, but the coating of plant-based proteins and waxes also extends the shelf life of the food.

Freiburg researchers have studied how changing their diet could influence the ecological footprint of Germans.

Article - 29/04/2021

Nanobodies for determining neutralising antibodies after corona infection

After contact with a pathogen, ideally our immune system generates neutralising antibodies to prevent a future infection. With NeutrobodyPlex, scientists from Reutlingen and Tübingen have developed a highly specific test procedure based on single-domain antibodies (nanobodies) that can be used to easily and reliably determine the quality of the immune response against the novel coronavirus.

Population growth and the increasing standard of living make our society face big ecological challenges: Climate change, littering of the seas, dwindling agricultural areas, resource scarcity. Bioeconomy aims at replacing fossil by regenerative resources and at using advanced and sustainable technologies based on biological knowledge and principles.

The BioSinn project found products and applications for which biodegradation at the end-of-life is a real option. 25 fact sheets answer technical and regulatory questions for each application. The market volume of these applications was also estimated: in Germany it is about 170,000 tonnes, in the European Union about 1 million tonnes per year!

The study “Life and Biological Sciences and Technologies as Engines for Bio-based Innovation”, funded by the European Commission, DG Research and Innovation has been published and is now available for download from the website of the Publications Office of the European Union.

Atriva Therapeutics GmbH, a company that is pioneering the development of therapies for the treatment of viral infections, has secured up to €11.4 million in federal funding. The company, founded in 2015, announced today that it was selected for research funding from the German Federal Ministry of Education and Research (BMBF). Atriva will use the funds to advance its drug ATR-002 towards market maturity as quickly as possible.

Protecting the global climate is an undertaking that presents both industry and society with a major task. It will not be possible to achieve the climate targets simply by limiting global emissions, by saving carbon dioxide (CO2). This is because there will continue to be unavoidable CO2 emissions that will nevertheless have to be compensated.

Genetically enhancing a patient's immune cells by adding therapeutic genes to them outside the body is regarded as a promising new treatment approach in oncology. However, the production of these therapeutic cells using viruses is not only expensive but time-consuming. Researchers at the German Cancer Research Center (DKFZ) have developed an innovative non-viral vector that can efficiently introduce therapeutic genes into immune cells.

Article - 14/04/2021

Calling for quality seal for implants

Today's seniors are older and more active, which is why implants remain in the body longer and are subjected to greater strain than before. Improved surfaces are expected to ensure that the implants heal and integrate into the bone optimally. In an interview with BIOPRO, Dietmar Schaffarczyk, CEO of Konstanz-based stimOS GmbH, explains why a voluntary quality seal makes sense and gives consumers a better chance of recognising high-quality…

Evotec SE announced today the launch of beLAB2122 in the Rhine- Main-Neckar region to efficiently advance first-in-class therapeutic concepts into investable drug discovery projects. Mediated and supported by BioRN, Evotec’s newest BRIDGE brings together the European Molecular Biology Laboratory (“EMBL”), the German Cancer Research Center (“DKFZ”), the Goethe University Frankfurt, Heidelberg University and the University of Tübingen.

Press release - 08/04/2021

How to enhance innovative value chains in the bioeconomy in the Alpine Space?

The European Interreg project AlpLinkBioEco in comes April 2021 to a successful end. The final conference of the project was conducted on the 31st of March 2021 and attracted over 160 participants from different parts of Europe. AlpLinkBioEco, of which BIOPRO Baden-Württemberg is a partner, has been running for three years (2018-2021) as part of the EU-Strategy for the Alpine Region (EUSALP).

Quantum Technology Ulm - 08/04/2021

Diamonds for life sciences innovations

The world's first commercial quantum computer,’IBM Q System One’, is now in operation in Ehningen near Stuttgart. This is a major leap forward in quantum technology in Germany. It marks the point at which conventional computers reach their limits. The University of Ulm is involved in three of six collaborative projects being funded by the Baden-Württemberg Ministry of Economic Affairs, Labour and Housing Construction.

Alternative source of protein - 07/04/2021

Smart insect farms as sustainable protein sources of the future

It is estimated that by 2050, if not before, the world's population will have grown so much that it will be difficult to provide adequate supplies of food for everyone. It is therefore high time to look for alternatives. One option could be insects as an environmentally friendly source of protein for humans and animals. The start-up company Cepri is developing smart insect farms with the goal to make primary production, which is not yet…

European project with participation of the University of Hohenheim investigates how unprofitable fields can be used sustainably while adding value with renewable raw materials.

Press release - 01/04/2021

Joint Masterplan on bioeconomy in the Alpine macro-region unveiled

AlpLinkBioEco Interreg project presents one of its main results.

CureVac N.V., a biopharmaceutical company developing a new class of transformative medicines based on mRNA and Celonic Group, a premium biopharmaceutical Contract Development and Manufacturing Organization specializing in the development and production of Advanced Therapy Medicinal Products and mammalian cell line-expressed bio-therapeutics, announced their partnership for the production of CureVac’s mRNA-based COVID-19 vaccine candidate, CVnCoV.

Tumor vaccines can help the body fight cancer. Mutations in the tumor genome often lead to protein changes that are typical of cancer. A vaccine can alert the patients' immune system to these mutated proteins. For the first time, physicians and cancer researchers from Heidelberg and Mannheim have now carried out a clinical trial to test a mutation-specific vaccine against malignant brain tumors.

Immunotherapy using checkpoint inhibitors is effective in around a quarter of patients with liver cancer. However, to date, physicians have been unable to predict which patients would benefit from this type of treatment and which would not. Researchers from the German Cancer Research Center have now discovered that liver cancer caused by chronic inflammatory fatty liver disease does not respond to this treatment. On the contrary: in an…

Microfluidics in medical technology - 24/03/2021

Ultra-compact: valves with shape memory actuators

Karlsruhe-based company memetis shows that this is possible. Intelligent components for controlling fluids open up huge potential in the medical technology and biotechnology sectors - from vaccine development and cell line analysis to drug research and point-of-care solutions.

AFYREN secures procurement of sugar beet co-products, major feedstock for industrial- scale production of its sustainable chemicals.

CureVac N.V., a global biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid (mRNA), today announced the publication of preclinical data demonstrating that their COVID-19 vaccine candidate, CVnCoV, protects against challenge infections with the SARS-CoV-2 Variant of Concern B.1.351 and a strain of the original SARS-CoV-2 B1 lineage (BavPat1) in a transgenic mouse model.